Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational study of CYT-0851

Next Previous
Trial Profile

A registrational study of CYT-0851

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emzadirib (Primary)
  • Indications Ovarian cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 30 Jun 2023 According to a Cyteir Therapeutics media release, the company discontinued development of CYT-0851 as overall clinical efficacy data of phase I study did not meet company's criteria to advance the program into the next phase of clinical development.
  • 30 Jun 2023 Status changed from planning to discontinued, according to a Cyteir Therapeutics media release.
  • 23 Mar 2023 According to a Cyteir Therapeutics media release, the company plans to start this study in the second half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top